Hyperactive delirium in dementia with Lewy bodies — MRCEM SBA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Give intramuscular lorazepam, investigate and treat the suspected infection, and admit under acute medicine.
The acute loss of attention and orientation is a change from her established dementia and suggests delirium. Fever, productive cough, tachypnoea and focal crackles point to a respiratory infection that needs prompt medical investigation and treatment; assessment for delirium, including a 4AT when feasible, should accompany this care. Reassurance and de-escalation were appropriate first steps, but they have failed and her behaviour now prevents essential care. An intramuscular medicine may therefore be needed to make assessment and treatment safe. Dementia with Lewy bodies is the decisive prescribing constraint. Haloperidol is contraindicated because of the risk of serious neurological adverse effects, so A is unsuitable despite its otherwise appropriate medical plan. Intramuscular lorazepam is an option for urgent tranquillisation when oral medication is not possible; use a cautious dose and monitor closely for sedation and respiratory compromise. B cannot address the immediate situation because she refuses oral medication; antipsychotics also require particular caution in Lewy body dementia. C chooses a suitable immediate route and agent, but suspected infection with delirium calls for medical rather than psychiatric admission. E preserves the preferred non-drug approach, but its continuation alone is insufficient while she remains a danger and essential treatment is obstructed.
Reference: NICE CG103: Delirium — recommendations (18 January 2023) — https://www.nice.org.uk/guidance/cg103/chapter/Recommendations NICE NG10: Violence and aggression — recommendations (2015) — https://www.nice.org.uk/guidance/NG10/chapter/recommendations MHRA: Haloperidol (Haldol) — reminder of risks in elderly patients with delirium (10 December 2021) — https://www.gov.uk/drug-safety-update/haloperidol-haldol-reminder-of-risks-when-used-in-elderly-patients-for-the-acute-treatment-of-delirium